Introduction
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document recommends the use of inhaled corticosteroids (ICS)/long-acting Byagonist (LABA) combinations as initial treatment only in specific subgroups of patients with chronic obstructive pulmonary disease (COPD); particularly in those at increased risk of future exacerbations [1] . GOLD defines these patients as those having severe or very severe airflow limitation (forced expiratory volume in Is (FEVI) <50% predicted) and/or two or more exacerbations (or one exacerbation requiring hospitalisation) in the previous year (GOLD groups C and D) [l[. For There were no significant differences between treatments in trough FEV1 at any of the other visits ( figure S1 in the online supplementary material), and no significant differences between treatments in individual timepoint FEV1 at either week 12 or week 26 ( 
